The Prioritisation and Risk Evaluation of Medicines in the EnviRonment project (PREMIER) has just kicked off with a clear aim: to contribute to a more sustainable future by minimising the environmental impact of medicines. Teamit is a partner in this project and will drive excellence on general and legal management aspects, whilst leading the communication and dissemination strategy.
The current model to assess and minimise the impact of pharmaceuticals in the environment and the associated health risks is time consuming, costly, and inefficient and requires intensive animal testing. To address this reality, 25 leading public and private organisations have come together in the PREMIER Consortium. In the next 6 years, they will jointly design a novel and transparent information and evaluation system for identifying and addressing environmental risks of medicines, especially for those with limited data availability. The project will initially focus on case studies for a selection of 25 pharmaceutical components. Ultimately, PREMIER aims to foster a new approach to the development of medicines to make this process more environmentally friendly and cost-efficient. This also includes the development of innovative tools and models to reduce the need for animal testing.
The PREMIER Consortium is formed by 10 EFPIA companies and 15 academic institutions and SMEs. Radboud University Nijmegen coordinates the project which is led by the pharmaceutical company AstraZeneca AB.
Teamit was involved in drafting the proposal, building the public-private partnership and negotiating the Consortium Agreement. It will now take responsibility for general and legal management aspects and will also design and implement the communication and dissemination strategy.
PREMIER has a total budget of € 9 Million. It has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 875508. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.